WallStSmart

DocGo Inc (DCGO)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 21698% more annual revenue ($65.77B vs $301.71M). MRK leads profitability with a 13.6% profit margin vs -62.2%. MRK earns a higher WallStSmart Score of 50/100 (D+).

DCGO

Hold

36

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 6.7Quality: 5.5
Piotroski: 3/9Altman Z: -1.24

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DCGOUndervalued (+53.4%)

Margin of Safety

+53.4%

Fair Value

$1.56

Current Price

$0.49

$1.07 discount

UndervaluedFair: $1.56Overvalued
MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$128.66

$47.70 premium

UndervaluedFair: $80.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DCGO2 strengths · Avg: 9.5/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.229/10

Conservative balance sheet, low leverage

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

DCGO4 concerns · Avg: 2.5/10
Market CapQuality
$54.93M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-141.9%2/10

ROE of -141.9% — below average capital efficiency

Revenue GrowthGrowth
-21.3%2/10

Revenue declined 21.3%

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DCGO

The strongest argument for DCGO centers on Price/Book, Debt/Equity.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : DCGO

The primary concerns for DCGO are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

DCGO profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

DCGO carries more volatility with a beta of 1.00 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 36/100). DCGO offers better value entry with a 53.4% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DocGo Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DocGo Inc. is an innovative mobile healthcare service provider that enhances patient access and optimizes healthcare delivery through its advanced logistics and telehealth solutions. Specializing in urgent care, diagnostic testing, and health screenings, DocGo addresses critical healthcare needs across various settings while significantly improving patient experiences. With a commitment to innovation and expanding healthcare accessibility, the company stands out in the rapidly evolving healthtech sector, positioning itself as a compelling investment opportunity for institutional investors seeking both sustainable growth and positive social impact.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?